2026-01-21 02:15Summary of the Conference Call Record Company Overview - The document discusses Zhaoyan New Drug, a leading company in the domestic safety evaluation (安评) sector, focusing on its performance forecast for 2025 and the impact of various factors on its financial results [1][2]. Key Financial Metrics - Revenue Forecast: Zhaoyan New Drug expects to achieve revenue between 1.573 billion to 1.738 billion yuan in 2025, representing a year-on-year decrease of approximately 13.9% to 22.1% [1]. - Net Profit: The company anticipates a net profit attributable to shareholders of 233 million to 349 million yuan, reflecting a significant year-on-year increase of about 214.0% to 371.0% [1]. - Non-recurring Net Profit: The forecast for non-recurring net profit is approximately 246 million to 370 million yuan, indicating a substantial increase of around 945.2% to 1,467.7% year-on-year [1]. Core Insights - Biological Assets Contribution: The fair value changes of biological assets are expected to contribute approximately 452 million to 499 million yuan to net profit, marking a significant turnaround from previous losses. This is driven by rising market prices and natural growth of the assets [1]. - Laboratory Services Impact: The net profit from laboratory services and other businesses is projected to be between -206 million to -130 million yuan, indicating a negative shift year-on-year due to intense competition in the industry [2]. Additional Important Points - Market Dynamics: Zhaoyan New Drug benefits from the digestion of existing orders and the transmission of new R&D demands to clinical CROs, alongside its unique integrated resources for experimental monkeys, which positions the company for further performance release [2].